We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Warning Letter to Lupin Pharmaceuticals
FDA Issues Warning Letter to Lupin Pharmaceuticals
July 6, 2009
Lupin products manufactured at its Mandideep, India, facility were cited for multiple GMP violations in a recent FDA warning letter.
Correction: The July 2009 issue of Drug GMP Report incorrectly reported that products manufactured at Lupin Pharmaceuticals’ Mandideep facility in India were placed under an import alert after receiving a warning letter from the FDA. The facility did receive a warning letter for several GMP violations but no import alert was issued. FDAnews regrets the error.